Plante Moran Financial Advisors’s Cytek Biosciences CTKB Stock Holding History

Plante Moran Financial Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$323	Buy	+73	New	+$312	﹤0.01%	1284

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

CFM

Catalyst Funds Management Sydney NSW, Australia $1.78B AUM 107.3% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Plante Moran Financial Advisors's CTKB Position: Q2 2026 in Review

Plante Moran Financial Advisors opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 73 shares worth $323. The stake represents ﹤0.01% of the portfolio and ranks #1284 among its holdings.

55 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Plante Moran Financial Advisors held 73 shares of Cytek Biosciences worth $323 as of Q2 2026.
Cytek Biosciences was a new Plante Moran Financial Advisors position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #1284 holding.
55 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.